Fulminant myocarditis following SARS-CoV-2 mRNA vaccination rescued with venoarterial ECMO: A report of two cases
Perfusion
; 38(1 Supplement):100-101, 2023.
Article
Dans Anglais
| EMBASE | ID: covidwho-20244280
ABSTRACT
Objectives:
Cases of fulminant myocarditis after mRNA COVID-19 vaccination have been reported. The most severe may need venoarterial extracorporeal membrane oxygenation (V-A ECMO) support. Here we report two cases successfully rescued with V-A ECMO. Method(s) We included all the cases supported with V-A ECMO for refractory cardiogenic shock due to myocarditis secondary to a mRNA SARS-COV2 vaccine in the high-volume adult ECMO Program in Vall Hebron University Hospital since January 2020. Result(s) We identified two cases (table). One of them was admitted for out-of-hospital cardiac arrest. In both, a peripheral V-A ECMO was implanted in the cath lab. An intra-aortic balloon pump was needed in one case for left ventricle unloading. Support could be successfully withdrawn in a mean of five days. No major bleeding or thrombosis complications occurred. Definite microscopic diagnosis could be reached in one case (Image, 3). Treatment was the same, using 1000mg of methylprednisolone/day for 3 days. A cardiac magnetic resonance 10 days after admission showed a significant improvement in systolic function and diffuse oedema and subepicardial contrast intake in different segments (Image, 1-2). Both patients were discharged fully recovered. Conclusion(s) V-A ECMO should be established in cases of COVID-19 vaccine-associated myocarditis with refractory cardiogenic shock during the acute phase. (Table Presented).
adult; adverse drug reaction; bleeding; cardiogenic shock; cardiovascular magnetic resonance; case report; clinical article; complication; conference abstract; drug withdrawal; edema; extracorporeal oxygenation; female; fulminant myocarditis; heart left ventricle; hospital discharge; human; intraaortic balloon pump; male; myocarditis; nonhuman; out of hospital cardiac arrest; Severe acute respiratory syndrome coronavirus 2; side effect; thrombosis; university hospital; vaccination; veno-arterial ECMO; messenger RNA; methylprednisolone; SARS-CoV-2 vaccine
Texte intégral:
Disponible
Collection:
Bases de données des oragnisations internationales
Base de données:
EMBASE
Les sujets:
Vaccins
langue:
Anglais
Revue:
Perfusion
Année:
2023
Type de document:
Article
Documents relatifs à ce sujet
MEDLINE
...
LILACS
LIS